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doi:10.1016/j.ejvs.2011.06.012Abstract Objective: The outcomes for patients after endovascular treatment of abdominal
aortic aneurysm (AAA) are determined primarily by the endpoints of death and endoleaks,
the latter representing continued risk of rupture. The data of a multicentre registry were ana-
lysed with regard to the early outcome of stent-graft procedures for AAA and the complications
associated with this treatment. In addition, the results during follow-up were analysed by
determining mortality and endoleak development as separate endpoints and as a combined
endpoint defined as endoleak-free survival.
Setting: 38 European institutions of Vascular Surgery collaborating in a multicentre registry
project.
Patients and methods: 899 patients with AAA underwent between May 1994 and March 1998
elective endovascular repair (818 men and 81 women; mean age 69 years). 80 (8.9%) of the
patients had medical conditions that excluded them from open repair. 818 (91%) of patients
had a bifurcated device, 63 (7%) had a straight tube graft, and only 18 (2%) had an aorto-uni-
iliac device. Clinical examination and contrast-enhanced computed tomography was performed
at fixed follow-up intervals to assess increase or decrease of the maximum transverse diameter
(MTD). Endoleaks observed at follow-upwere discriminated into persistent endoleak and tempo-
rary endoleak. The latter is defined as single time observed endoleaks or with two or more nega-
tive imaging studies between observed endoleaks. Life-table analyses were used to calculate
the rates of freedom-from-endoleak (no endoleak at any time), freedom-from-persistent endo-
leak (no persistent endoleak), patient survival, and persistent-endoleak-free-survival.eeting of the European Society for Vascular Surgery, Paris, 1e4 October, 1998.
blished in Eur J Vasc Endovasc Surg 1999;17:507e16.
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S64 Ph. Cuypers et al.Results: The median follow-up of this patient series was 6.2 months. The ratio between
observed and expected follow-up data was 82% for the overall follow-up period. However, at
18 months of follow-up this rate was only 45%. The number of patients followed during this
period was sufficient to allow statistically meaningful assessment. The MTD in patients with
temporary endoleaks demonstrated a significant decrease at 6 to 12 months compared to preop-
erative values (mean 57 and 53 respectively, pZ 0.004). In patients with persistent endoleaks
there was no change between the preoperative and 6-month MTD (mean 57 and 60 mm respec-
tively). At 6 and 18 months freedom-from-endoleak was 83% and 74% and freedom-from-
persistent endoleak was 93% and 90%, respectively. The 18-month cumulative patient survival
was 88% and the main outcome measure, the persistent endoleak-free-survival was 79%.
Conclusions: The MTD decreases in patients with temporary endoleak, but not in patients with
persistent endoleak. Therefore, the use of the rate of freedom-from-persistent endoleak, re-
flecting absence of persisting endoleaks to estimate the prognosis with regard to the AAA, is
justified. Determining persistent endoleak-free survival appears a rational approach to provide
a realistic outlook for patients with stent-grafted AAA. The observed 18-month endoleak-free
survival reflects a satisfactory mid-term result.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Introduction
Following the initial successful application of stent-graft
treatment by Parodi et al. in 1991 the short-term efficacy of
endovascular abdominal aortic aneurysm (AAA) repair has
been documented in a number of publications.1-6 However,
with regard to mid- and long-term success much uncertainty
remains. Most studies dealing with the outcome of endo-
vascular treatment of AAAhave reportedon small numbers of
patients.Usually follow-up resultswerenotpresented in life-
table or Kaplan-Meier format, and the outcomes have not
been assessed from the patient’s perspective. Rather, the
physician’s view has been considered, taking into account
primarily procedural aspects such as access, graft deploy-
ment and function. The investigation of device failure and
the reporting of these events is essential to further appre-
ciate the advantages and disadvantages of endovascular AAA
treatment. Technical failures can perhaps be accepted if the
problem is resolved by a secondary endovascular interven-
tion or even by a surgical procedure.
From the patient’s perspective the possibility of dying,
either from a related or unrelated cause, is of greatest rele-
vance. Therefore, survival rate over time is the principal risk
to be assessed for the patient. But endoleaks are also impor-
tant. If an endoleak persists, the aneurysm remains at risk of
rupture. Like survival, the absence of endoleak is a time-
dependent outcome that may best be represented in a life-
table format as rate of freedom-from-endoleak. Moreover,
one may distinguish between freedom-from-endoleak for
absence of any endoleak, and freedom-from-persistent
endoleak if only a persistent endoleak is the event of
interest. Considering mortality and persistent endoleak as
a combined endpoint, defined as “persistent-endoleak-free
survival” appears a simple and practical approach to provide
a realistic prognosis to a patient ofwhat can be expected if he
or she chooses to undergo this form of treatment.
This report documents the results of a multicentre
registry, organised by the “EUROSTAR” collaborators’ group,
with regard to the procedural and follow-up data of patients
treated by stent-graft techniques in a large number of
European vascular institutions.7 The early outcome andperioperative complications are outlined. In addition, with
regard to the follow-up period, freedom-from-endoleak,
freedom-from-persistent endoleak, patient survival and
persistent endoleak-free survival rates are assessed.
Because there is considerable variation with regard to the
estimated rates of complications and endoleaks between
different institutions, this large-scale study was performed
to provide a realistic appraisal of the outcome of endovas-
cular AAA repair in Europe.
Methods
The study period extended from April 1994 to April 1998.
Two periods of patient enrolment could be distinguished.1
Five hundred and thirty-five patients operated upon after
1st July 1996 had their procedures notified to the EURO-
STAR Data Registry Center prior to operation. Data on
patients operated upon before the 1st July 1996 were
retrieved from hospital notes and other records retro-
spectively. This cohort, which consisted of 364 patients,
was treated in 19 centres. Therefore, this study involved
the data on a total of 899 patients. They were provided
from 38 centres in different European countries. Ten of the
centres had recruited less than five patients, 11 centres five
to 15 patients, 14 centres 16 to 50 patients, two centres 51
to 100 patients, and one centre more than 100 patients.
Of the 899 patients 818 (91%) were men, and 81 (9%)
were women. The mean age was 69 years (range 37 to 90).
The American Society of Anaesthesiology (ASA) risk classi-
fication was used to represent the patient’s risk profile. The
distribution in the different categories is represented in
Table 1. Factors that may have influenced the decision to
perform endovascular treatment rather than an open
surgical procedure included marked obesity in 192 patients
(21%), previous laparotomy in 229 patients (25%), unfit to
undergo an open abdominal aortic procedure in 77 (9%),
and unfit to tolerate general anaesthesia in 6 (3%).
Detailed preoperative imaging of the abdominal aorta
and iliac arteries by contrast-enhanced computed tomog-
raphy (CT), and aortography was performed in 99% and 97%
respectively. The median maximum transverse diameter
Table 1 Risk factors in 899 patients with stent-graft
treatment for AAA.
SVS-ISCVSa risk score
0 1 2 3
Associated diseases % of patients
Diabetes mellitus 71 7 2 0.2
Smoking 54 24 14 8
Hypertension 53 32 12 3
Hyperlipidaemia 70 20 4 6
Cardiac status 50 24 22 4
Carotid disease 88 9 2 1.5
Renal status 86 11 2 0.6
Pulmonary status 70 18 10 2
ASA physical status
classification
No. of patients (%)
ASA I 77 (8.6)
ASA II 334 (37.1)
ASA III 408 (45.4)
ASA IV 80 (8.9)
a Society of Vascular Surgery-International Society of Cardio-
vascular Surgery, North American Chapter.
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quartile range (IQR) of 48 to 60. The median infrarenal neck
diameter was 22 mm (IQR 21 to 24), and the median neck
length was of 25 mm (IQR 20 to 32). An anatomical classi-
fication had been described previously.7 In the study 17% of
the patients demonstrated a type A morphology (normal-
sized aortic cuff at the bifurcation), 55% had a type B
(normal common iliac arteries), 17% type C (partial aneu-
rysmal common iliac arteries), 7% type D (proximal aneu-
rysmal common iliac artery with small distal normal
segment) and 5% had a type E (completely aneurysmal
common iliac arteries). 97% of patients had symmetrical
morphology, and the others had iliac arteries of different
anatomical categories at the two sides.
Commercially manufactured devices for stent-graft
treatment was used in the majority of patients in this
series, but twopatients hadadevice implanted that hadbeen
constructed by the physician.8,9 Most participating centres
were assisted during their first series of cases by a vascular
surgeon or a radiologist who had pioneered this therapeutic
approach, and had extensive experience acquired with the
type of device used. Most commonly procedures were per-
formed in the operating room using mobile fluoroscopy
equipment. Completion angiograms were performed to
assess the procedural results. Vascular surgeons and radiol-
ogists usually worked together in teams. There were differ-
ences between centres with regard to the use of systemic or
regional heparinisation, the application of coil embolisation
of side-branches prior to stent-graft, and the preference for
a unilateral or bilateral common femoral artery exploration
with arteriotomy for the implantation of bifurcated devices.
Data collection and assessment
Standardised Case Record Forms weremade available by the
EUROSTAR organisation to participating institutions from
July 1996. During the prospective study period the informedconsent registration page was faxed preoperatively to the
Data Registry Centre. Completed forms with baseline and
clinical data, summarised information on the CT and angio-
graphic findings, details of the stent-graft procedure, and
observations from the completion angiography were sent to
the Data Registry Center after discharge of the patient.
Subsequently, follow-up formswith clinical and imaging data
were submitted after each outpatient visit. Follow-up data
consisted of information on the patient’s general condition
as well as the presence or absence of endoleaks and changes
in the MTD of the aneurysmal sac. In the case of death or
conversion to an openprocedure details of these eventswere
recorded as they occurred.
The imaging follow-up protocol included a CT-scan at 1, 3,
6, 12, 18 and 24 months, and yearly thereafter. An intra-
arterial DSA was scheduled at 1 month and 12 months. A
duplex studywas performedat the same times as CT-scanning
until the 12-month follow-up visit. For this study combined
usewasmadeoffindingsatCT,DSAandduplexassessments. If
abnormalities were observed with one modality this was the
recorded finding. The prime imaging parameters determined
preoperatively and with each follow-up visit were: (1) the
maximum transverse diameter (MTD), and (2) the presence or
absence of perigraft flow in the aneurysmal sac, i.e. endo-
leakage. Endoleaks were distinguished as early endoleak,
that is an endoleak observedbeforedischarge, and endoleaks
at follow-up, that is all endoleaks observed at 1 month
imaging studies and/or on subsequent follow-up studies.
Endoleaks at follow-up included residual early endoleaks that
continued to exist after 1 month, and those which arose de
novo. Endoleaks were also classified by site: proximal
attachment,midgraft level, distal attachment site, and those
originating from side-branches.Data analysis and study endpoints
All data were recorded on a computerised database.
Operative technical details, such as the type of anaes-
thesia, and the need for adjuvant procedures were recor-
ded. In addition, information on the duration of the
procedure, duration of fluoroscopy, duration of intensive
care unit (ICU) stay, and duration of hospital administration
were entered. Early results were represented by the
mortality at one month, and the occurrence of systemic
and local (arterial) complications. All continuous variables
were expressed as median values and interquartile ranges.
Results after discharge were recorded in terms of late
complications, and the development of endoleaks during
follow-up. Two patterns of endoleak at follow-up were
distinguished in this analysis according to the frequency
and the time period of identification:
(1) persisting endoleaks, which were observed either on at
least two subsequent follow-up visits or with one
negative study in between the two positive studies,
(2) temporary endoleaks, which were all other endoleaks,
e.g. a single-time-observed leak, or more than one
negative study between twopositive studies, i.e. remote
occurrence.
Changes in the MTD of aneurysms between the preop-
erative measurements and imaging examinations during
follow-up were correlated with the occurrence of
Table 2 Adjuvant procedures in 899 patients with stent-
graft treatment for AAA.
No. of procedures
Endovascular procedures (total) 162
Angioplasty/stent 132
Coil embolisation 30
Surgical procedures (total) 84
Endarterectomy 14
Iliofemoral bypass 4
Crossover femorofemoral bypass 11
Transposition of hypogastric artery 3
Decoiling of iliac artery 2
Other arterial reconstruction 43
Miscellaneous 7
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ranges were used to represent these values. For this
correlation a paired Wilcoxon test was used. Life-table
analysis and Kaplan-Meier curves were constructed to
represent the freedom-from-endoleak (no endoleak at
follow-up), freedom-from-persistent endoleak (no persis-
tent endoleak at follow-up), and patient survival. In addi-
tion, the cumulative survival and freedom-from-persistent
endoleak data were combined into a persistent endoleak-
free survival rate.
Results
Devices and procedures
Of the 899 patients, 797 received a modular bifurcation
device, 21 a uni-piece bifurcation device, 63 an aorto-
aortic straight tube stent-graft, and 18 an aorto-uni-iliac
device. In the last group the procedure included a femo-
rofemoral crossover bypass, and stent occluder of one
common iliac artery. The devices used were Stentor (331
patients), Vanguard (455 patients), EVT (38 patients),
Talent (63 patients), AneuRx (10 patients), and
physician-constructed prototype devices (two patients).
Seven hundred and twenty-eight (81%) procedures were
performed under general anaesthesia, 152 (17%) under
spinal anaesthesia, and five (0.6%) under local anaesthesia.
In 14 patients the type of anaesthesia was not indicated.
The median operation time was 140 min (106e210); the
fluoroscopy time was 27 min (18e40); the length of ICU stay
was 21 h (18e24); and the duration of postprocedure
hospital stay was 7 days (5e10). In 239 patients, 246
adjuvant procedures were performed. One hundred and
fifty-five patients had endovascular procedures and 84
patients had open surgical procedures (Table 2).
Early complications
Intraoperative conversion of the initial intervention into an
open surgical procedure was required in 18 patients (2%),
and another two were subsequently converted to open
operations during the first postoperative month. There
were 29 early deaths (3.2%). Of these, 20 occurred during
the hospital stay, and nine shortly thereafter. Causes ofdeath included cardiac events in eight, multi-organ failure
or sepsis in six, pulmonary failure in two, colonic ischaemia
in one, haemorrhage in two, and cerebral complications in
three patients. The mortality rate correlated significantly
with the ASA category with 10 deaths (12.5%) in patients in
ASA IV category, and 19 deaths (2.3%) in patients in cate-
gories I to III (p Z 0.001).
Failure to complete the implantation occurred in 26
patients. The reasons included migration, inability to deploy
the device, inability to connect an iliac limb to amain device,
and graft thrombosis. In 18, conversion to an open procedure
was required. In five patients a femorofemoral bypass was
performed to bypass an inadvertently caused iliac artery
occlusion, and in three the procedure was abandoned. Early
non-fatal systemic complications occurred during hospital
admission in 117 (13%) patients. The majority of these were
cardiac in origin. Device- and procedure-related adverse
events other than the need for conversion to an open
procedure during or after the operation occurred in 13% and
access-site-related complications in another 13% (Table 3).
Early endoleak
In 162 patients, 174 endoleaks were identified before
discharge. Of these, 39 were at the proximal attachment
site, 29 at mid-graft level, 52 at the distal site (together
defined as graft-related endoleaks), and 54 consisted of
backbleeding from side-branches (non-graft-related).
Within 6 months 72 (41%) of the endoleaks had resolved
spontaneously. Of the resolved endoleaks, 12were proximal,
15 mid-graft, 20 distal, and 25 side-branch backbleeding. A
secondary endovascular repair was undertaken in 12
patients, and an open procedure in one. Six patients had
endoleaks at discharge that were related to failure to
complete the stent-graft procedure. Three of these under-
went a conversion within 6 months, and three patients were
managed conservatively. Fifty-four endoleaks persisted at 6
months, 39 (32%) were graft-related and 15 (28%) were non-
graft-related. This difference was not significant. In 29 the
course was unknown because of loss of follow-up or because
of the timing of follow-up relative to this study.
Of the 39 proximal endoleaks one was dealt with by
conversion to open surgery during the admission, three by
open repair at a later admission, four by late endovascular
repairs, and 12 endoleaks closed spontaneously. Fifteen
proximal endoleaks (38%, 15/39), and 39 endoleaks at other
sites (29%, 39/135) were still present after 6 months, rates
that were not significantly different.
Complications at follow-up
The median follow-up period at the time of data analysis
was 6.2 months (range 0 to 48). This is indicative of a high
rate of patient recruitment during the most recent part of
the study period. The completeness of follow-up informa-
tion is shown in Table 4. The overall ratio of observed to
expected follow-up visits, corrected for interval deaths was
82%. However, after 1 year there was a marked drop in this
ratio to 45% at 18 months.
Adverse systemic events were observed after the first
postoperative month in 3 to 4% of patients in every 3months’
Table 3 Complications during stent-graft procedures or during hospital admission in 899 patients.
No. of patients No. of complications
Systemic complications 117
Cardiac 36
Renal, urologic 32
Pulmonary 26
Stomach, hepatobiliary, pancreas, bowel 17
ARDS, sepsis 16
Cerebral 10
Laparotomy because of systemic complications 4
Miscellaneous 25
Procedure- and device-related problems in: 121
Advancing of delivery system 21
Deployment of device 32
Rupture of balloon 20
Conversion to open procedure 18
Device migration 16
Introducer shear tear 9
Device/limb occlusion 8
Crossover bypass 4
Aortic/arterial rupture of tear 3
Iliac limb detachment 2
Access site/arterial complication 117
Dissection, peforation, arterial damage 13
Secondary bleeding, haematoma, false aneurysm 59
Arterial thrombosis 20
Arterial emboli, micro-emboli 10
Wound infection, skin necrosis, lymphocoeles 13
Limb loss 1
Miscellaneous 16
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of conditions, usually not related to the procedure. Cardio-
vascular disease constituted 21 to 32% of events in each
observation interval. Procedure or device-related compli-
cations occurred in 5 to 9% (Table 5). In six patients (0.7%) the
aneurysm ruptured during follow-up. In two of these the
existence of an endoleak had been demonstrated prior to
rupture and one had a stent-graft infection. Further inter-
ventions for procedure and device-related complications
were required during the subsequent follow-up in 3 to 4.7% of
the patients in each 3-month follow-up interval. Most of the
interventions were by a transfemoral approach.Table 4 Numbers of registered and expected data at
different follow-up periods.
Follow-up
(months)
Observed no.
of patients
Expected no.
of patients
Ratio observed/
expected
Predischarge 865 882 98%a
1 713 845 84%
3 623 745 84%
6 500 636 79%
12 289 410 70%
18 129 283 45%
Total 3118 3801 82%
a Corrected for deaths during admission. 2% difference due to
surviving patients with early conversion.Endoleak at follow-up
Endoleaks at follow-up developed in 1-5% in each 3-month
follow-up interval (Table 6). Proximal endoleaks were
relatively frequent during early follow-up, but were
not observed after the sixth postoperative month. In
contrast, endoleaks originating from the graft itself and
distal endoleaks were noted throughout the follow-up
period up to 18 months postoperatively. New endoleaks
from lumbar arteries did not develop after 6 months. A
total of 64 reinterventions (53 transfemoral, 10 trans-
abdominal and one crossover bypass combined with an
endovascular procedure) were performed for endoleaks.
Of these reinterventions were successful in resolving the
endoleak.
The freedom-from-endoleak rate, representing the
absence of an endoleak at any time during follow-up, was
74% (S.E. 3%) at 18 months postoperatively. The freedom-
from-persistent endoleak rate, which was based on the
occurrence of persistent endoleaks only, was 90% (S.E. 2%)
at 18 months of follow-up (Fig. 1).
Aneurysm shrinkage
The median maximum transverse diameter (MTD) of the
aneurysms in the overall group decreased significantly from
a median preoperative value of 55 mm (48e60) to 50 mm
(42e58) at 6 to 12 months postoperatively (pZ 0.0001). In
Table 5 Procedure and device-related complications and interventions during the first 18 months of follow-up.
Observation period (months) 1 3 6 12 18
Number of patients followed in interval 713 622 500 289 128
Number (%) of patients with complication 50 (7) 53 (9) 46 (9) 30 (10) 12 (14)
Number of procedure/device related complications
Graft migration 2 2 9 5 2
Graft stenosis 5 5 6 2 1
Graft thrombosis 7 9 5 6 1
Leakage into saca 28 22 17 10 5
Rupture of aneurysm 1 1 2 1 1
Further transfemoral intervention 15 13 15 14 8
Further transabdominal intervention 3 3 3 4 3
Further extra-anatomical intervention 1 5 1 2 1
Interventions for endoleak/total interventions 12/19 12/21 16/19 13/20 11/12
a Endoleaks noted by observers as a clinically significant complication. Endoleak may be recorded during more than one interval. These
figures do not equal numbers of new endoleaks in Table 6 which were based on serial imaging.
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difference between the preoperative and 6- to 12-month
values, 55 mm (48e60) and 49 mm (42e56) respectively
(pZ 0.0001). In contrast, patients with persisting endoleaks
had no decrease of the median MTD, preoperatively 57 mm
(50e65), and after 6-12 months 60 mm (54e63). Patients
with temporary endoleaks demonstrated a significant drop
in MTD, from 57 mm (54e63) to 53 mm (48e53) (pZ 0.004).
Survival and persistent endoleak-free survival
Sixty patients died in the two years following the stent-
graft procedure. In only two patients was rupture of the
aneurysm the cause of death. The cumulative survival rate
at 18 months was 88% (S.E. 2%). The persistent endoleak-
free survival, based on the combined patient survival and
freedom-from-persistent endoleak data was 79% (S.E. 2%)
at 18 months (Fig. 2).
Discussion
This series represents the collective experience of 38 groups
in European centres with stent-graft repair of AAA. Centres
that were involved from the beginning of the registry had
enrolled patients in the retrospective part of the study, and
this included their early experience with this technique. For
centres that joined the registry after 1st July 1996, it was
requested that they did not submit data on patients includedTable 6 Endoleaks at follow-up identified at different follow-u
Observation period (months) 1
Number of patients followed per interval 713
Number of patients (%) with new endoleak 57 (8)
Number of endoleaks and sites
Proximal attachment 18
Graft 9
Distal attachment 23
Re-injection from side-branch 14
(Patients with combination of endoleaks) (7)in their learning curve experience. Whilst differences in
treatment outcome may be influenced by the time period
within the study that the operation took place, and experi-
ence of the team, this was not the subject of the present
study. The main objective was to make a realistic assessment
of results obtained from endovascular aneurysm repair in
Europe today. The range of devices used represented all
available stent-grafts during the study period. The predomi-
nance (89%) of modular bifurcated grafts used was a reflec-
tion of the important role played by European physicians in
the development and early application of this type of
device.10,11 Data collection in this large multicentre series
was a laborious operation. The ratio between observed and
expected data was acceptable up to 12 months after opera-
tion, but declined to a disappointing 40% at 18 months.
Nevertheless, a meaningful analysis is possible.
A rational indication for the treatment of an AAA, either
by open or by endovascular surgery, may be based on the
premise that the mortality of treatment is less than the risk
of rupture within one year.12 The early mortality of endo-
vascular AAA-repair in recent studies varied from 0-6.6%.6-
8,10-14 The few studies comparing patients treated with
stent-grafts, with a contemporary group of controls treated
by open surgery, showed no difference in mortality.15,16 Our
findings included an overall operative mortality in 899
patients of 3.2%, and was significantly related to advanced
co-morbidity. For ASA IV patients it was 12.8%. Parodi’s
series, consisting of patients with contraindications for
open surgery, had a mortality of 8%.17 It is to be expectedp intervals.
3 6 12 18
622 500 289 128
32 (5) 17 (3) 13 (4) 2 (2)
3 3 d d
5 4 5 1
7 4 8 1
17 8 d d
d (2) d d
Figure 1 Kaplan-Meier curve for freedom-from-endoleak and
freedom-from-persistent endoleak.
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observed mortality will be substantially lower. It follows
that a meaningful comparison of open and endovascular
AAA-repair should preferably be made on the basis of
a randomised study in which selection bias is accounted for.
Until such a study is completed choice of treatment must
be based on personal preferences and economic factors. A
lower incidence of systemic complications, a shorter
duration of hospital stay, and a more rapid recovery favour
the endovascular procedure. But these advantages have to
be contrasted with the expense of the stent-graft and the
necessity for long-term follow-up by imaging techniques
because of the risk of late endoleak development.
Systemiccomplicationswereobserved in thepostoperative
period in13%,cardiac,pulmonary,and renaldysfunctionbeing
most frequently encountered. This incidence is almost iden-
tical with the 14 to 17% as reported by Brewster and May, but
higher than the 5% observed by Mialhe et al.10,15,16 In
comparison, the incidence of cardiac and pulmonary compli-
cations was considerably lower in the present study than in
a series of open operation reported in the Canadian Aneurysm
Study (4% vs. 15%, and 3% vs. 8%, respectively).18 This is in
agreement with the observations of Brewster et al., whoFigure 2 Kaplan-Meier curve for patient survival and
persistent endoleak-free survival.found, in a comparative study, a lower incidence of systemic
complications in the stent-graft-treated group.16
Initial exclusion of the aneurysm was achieved in 82% of
this series (737/899). An 18% incidence of early endoleaks is
in the middle of the reported range which varies from 12-
44%.5,10,11,14,17,19 The majority (69%, 120/174) of early
endoleaks were graft-related, which includes ineffective
seal at the attachment sites and leak from the graft itself.20
Thirty-one percent (54/174) of early endoleaks were still
present after 6 months, without much difference between
graft-related and non-graft-related endoleaks. Proximal
endoleaks persisted just as frequently (38%, 15/39) as other
endoleaks (29%, 39/135) until the sixth postoperative
month. This finding corresponded with the observations of
Matsumura and Moore, who found no difference in the
tendency of spontaneous closure between proximal and
other endoleaks.21 Endoleaks were associated with device
migration, graft thrombosis, deployment problems or failure
to connect the second iliac limb (inability to complete the
procedure) in 4% of patients (6/162). The availability of
adjunct devicecomponents, suchas anextra short aortic cuff
to seal the proximal attachment is essential.
Successful AAA exclusion results in a marked decrease in
aneurysm size. The presence of endoleaks, on the other
hand, may be associated with further expansion of the
aneurysm, and possibly rupture.22-26 Proposals for the
classification of endoleaks have been made by White
et al.19,20 These authors distinguished primary endoleaks,
existing from the initial procedure, and secondary or late
endoleaks, which develop de novo during follow-up. We
found it difficult to follow precisely this classification, as it
was impractical in a life-table analysis to distinguish
residual procedural endoleaks from endoleaks that develop
after the perioperative period. Therefore endoleaks at
follow-up, as defined for the purpose of this study, included
all endoleaks observed at 1 month or thereafter. Other
aspects of White’s originally suggested definitions were
applied in detail. We found that endoleaks originating from
the graft and distal attachment sites continued to occur
after 6 months of follow-up, whereas new proximal
attachment-site endoleaks and reinjection from side-
branches were not observed after this period.
Criteria for success have been outlined by the Ad Hoc
Committee for Standardised Reporting Practices in Vascular
Surgery of the Society for Vascular Surgery/International
Society for Cardiovascular Surgery.27 This committee distin-
guished between technical success and clinical success for
early postoperative results, and continuing success for late
results. These definitions each encompass a range of vari-
ables including graft thrombosis, migration, infection and
dilation at or adjacent to the aneurysm as endpoints. In our
view this approachwill remain the basis for amethodological
analysis of treatment results of endovascular AAA-repair.
However, a patient-oriented analysis as presented in the
present report seems justified. Theexpected short- and long-
term survival rate is the first andmost important information
required by the patient. We observed that only persistent
endoleaks were associated with instability (increase of
diameter) of aneurysms, and consequently a risk of late
rupture. This suggests that freedom-from-persistent endo-
leak is the secondmost important variable from the patient’s
point of view. Whilst survival and freedom-from-persistent
S70 Ph. Cuypers et al.endoleak should be calculated separately, a combined
endpoint “persistent endoleak-free survival” gives a realistic
and very valuable single measure of outcome. Additional
risks of treatment, including the possibility of endovascular
or open re-interventions, are also very relevant, but are less
likely to influence the patient’s choice of treatment.
In principle, Kaplan-Meier curves can be used to esti-
mate the risk of any event of interest after vascular inter-
ventions.28 However this technique has been utilised rarely
to demonstrate outcome of endovascular AAA-repair. May
et al. have used Kaplan-Meier curves to calculate rates of
survival and graft failure, and the Ad Hoc Committee for
Standardised Reporting Practices recommended the use of
the life-table method to report rupture-free survival and
stability of aneurysm size.27,29 Future assessment of these
different endpoints, and in addition the presently proposed
persistent endoleak-free survival by life-table or Kaplan-
Meier curves may allow, for example, the identification of
favourable anatomical configurations, and comparison
between different types of devices with regard to the risk
of untoward events during follow-up.
In conclusion, the cumulative survival rate at 18 months
in this series of patients was 88% and the persistent
endoleak-free survival rate was 79%. We believe these
figures represent a realistic appraisal of the outcome from
endovascular aneurysm repair in Europe at the present
time. Comparative studies based upon this type of data
analysis are required now to assess the efficacy of endo-
vascular repair relative to other types of treatment,
particularly conventional repair.
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